ARQL/Daiichi management is an example of incompetence
NSCLC
In Ph2, ARQL/Daiichi tested/analyzed PFS but did not get OS results. Then, Marquee Ph3 NSCLC trial was designed around OS as the primary endpoint. The trial has failed to meet its objectives. It was a major trial design crew-up.
HCC
The Ph2 results were great using Tiva in a capsule form. Then, ARQL started HCC Ph3 trial with Tiva in a tablet form assuming that Tiva efficacy and side-effects are the same in two forms. Now, ARQL/Daiichi have discovered that Tiva efficacy and side-effects are not the same in capsule and tablet forms. Tiva in tablet form has much more side-effect as it was learned from both Ph3 Marquee and ongoing HCC trials.
During the today CC, ARQL indicated that Tivantinib in a tablet form has a much higher Pharmacokinetics level (up to 3 times higher) and much higher side-effects.
